- Details
- At the 2024 LUGPA annual meeting, Scott Eggener reviews cutting-edge prostate cancer technologies, from screening and imaging to genomic testing and emerging treatments. He provides balanced perspectives on new innovations, emphasizing evidence-based adoption and cautioning against unproven expensive technologies. Biographies: Scott Eggener, Professor of Surgery (Urologic Oncology) and Radiology,...
|
- Details
- Oliver Sartor speaks with Russ Pachynski, Chris Maher, and Aadel Chaudhuri about their novel biomarker study in advanced prostate cancer. The discussion centers on their development of a cell-free DNA assay that examines both AR gene and enhancer alterations in mCRPC patients, showing significant prognostic value for treatment outcomes. Dr. Chaudhuri presents their discovery of a stemness signatur...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Bertrand Tombal challenges traditional salvage radiation approaches in high-risk EMBARK patients. Based on trial results showing enzalutamide's survival benefits, he advocates shifting from radiation-first to systemic ARTA treatment, with radiation as a secondary consideration. Biographies: Bertrand Tombal, MD, PhD, Chairman of the...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Daniel Spratt examines systemic therapy in post-operative biochemical recurrence, challenging universal hormone therapy with salvage radiation. He demonstrates varying benefits based on PSA levels and emphasizes treatment personalization using genomic classifiers and MMAI models. Biographies: Daniel Spratt, MD, Chair and Professor...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Derya Tilki leads a panel with Drs Tombal, Spratt, and Alicja Jereczek-Fossa examining salvage radiation timing, EMBARK trial interpretation, and treatment decision factors in biochemically recurrent prostate cancer, balancing PSA levels and patient-specific characteristics. Biographies: Derya Tilki, MD, Associate Professor of Urol...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Paul Nguyen analyzes treatment approaches for post-prostatectomy and salvage radiation biochemical recurrence, comparing SBRT versus whole pelvis radiation for lymph node metastases. He examines current evidence and ongoing trials informing treatment decisions. Biographies: Paul L. Nguyen, MD, MBA, FASTRO, Baldwin-Politi Distinguis...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Matthew Smith presents an overview of prognostic and predictive biomarkers in metastatic castration-sensitive prostate cancer, examining established factors like disease patterns and volume while highlighting the Decipher score's prognostic value. Biographies: Matthew Smith, MD, PhD, Oncologist, Professor of Medicine, Harvard Medic...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Robert Jones discusses the role of combination therapy in low-volume metastatic prostate cancer, examining evidence from PEACE-1 and meta-analyses that suggest potential benefits of triplet therapy (radiotherapy + ARPI + ADT) over doublet options despite not reaching statistical significance. Biographies: Robert Jones, PhD, Profess...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Oliver Sartor discusses the management of synchronous, low-volume, metastatic hormone-sensitive prostate cancer. The presentation analyzes data from major trials like PEACE-1 and ARASENS while addressing the benefits of prostate radiation and acknowledging the complexity of real-world treatment decisions. Biographies: Oliver Sartor...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Nicholas James presents an analysis of triplet therapy in prostate cancer treatment, examining evidence from the PEACE-1, ARASENS, and ENZAMET trials. Through network meta-analysis, he explores the comparative effectiveness of different treatment combinations and proposes a framework based on disease characteristics. Biographies: N...
|
